Eiji Nishio   Takanori Hayashi   Mao Akaza   Yukiko Hisatomi   Masahiro Hikichi   Takuma Fujii   Toshiaki Utsumi   Nobuhiro Harada   Yohei Shimono   
FEBS open bio 10(10) 2072-2080 2020年8月 [査読有り]
Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second-line therapeutic option for hormone therapy-resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease...